Release Date: 09-Jun-2022
"Global KRAS Inhibitors Market and Clinical Trials Forecast 2028" Report Highlights:
The identification of various mutations in the cancers has open new avenues for the development of targeted therapies in its management. Kirsten rat sarcoma viral oncogene homologue (KRAS) is one of the most frequently occurring mutated oncogene which aids in tumor development mainly in lung cancer, colorectal cancer, and pancreatic cancer. Over the last few years, scientists have done immense efforts to develop novel drug which can target this gene as an alternate to manage the cancer. Recently, small molecule inhibitor targeting KRAS mutations have emerged as breakthrough in the cancer therapeutics market.
Amgen has developed Lumakras which is the first (Solatraib) which is the first targeted drug which is approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. The drug was granted FDA approval on 28 May, 2021. The clinical trials with the drug demonstrated high efficacy and considerable increase in overall survival and progression free survival rates of NSCLC patients. The introduction of this drug I the market has demonstrated success in the market due to lack of competition. Apart from non-small cell lung cancer, researchers are also validating the role of Lumakras in other cancers including colorectal cancer, pancreatic cancer, and other solid tumors which have KRAS G12C mutations, which will also propel the growth of market.
The increasing adoption rates of Lumakras in short span of time has attracted several pharmaceutical giants to actively invest in this segment. Mirati Therapeutics is one of the leading giants which have developed Adagrasib which is an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C mutations. In 2022, US FDA has accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer. The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022.
Apart from small molecule inhibitors targeting KRAS, researchers are also evaluating several other approaches to target these mutations more efficiently. Researchers have designed several vaccines targeting KRAS which have shown promising success and safety in early stages of clinical trials. It has been shown that the durable and specific responses induced by KRAS vaccines can boost preexistent immune response and reverse functional deficits. Elicio Therapeutics has developed ELI-002 which is an investigational AMP therapeutic vaccine targeting KRAS-driven cancer. Currently, the vaccine is present in phase-I/II clinical trial for the management of patients with solid tumors, including colorectal cancer, or CRC, or pancreatic ductal adenocarcinoma, or PDAC.
To enhance the efficacy of these drugs in the management of cancer, scientists are evaluating the role of combinational therapies which are present in early stages of clinical trials. For instance in 2022, Elicio Therapeutics and Regeneron has signed supply agreement and collaboration to access the safety and tolerability of ELI-002 in combination with Libtayo in patients with KRAS driven cancers including non-small cell lung cancer, colorectal cancer, pancreatic cancers, and others. The trial is expected to begin in 2023. In addition, Agenus has also entered into collaboration with Tagrovax to evaluate the combination of Targovax’s TG mutant KRAS cancer vaccines with Agenusandacute;s clinically validated and FDA approved QS-21 STIMULON adjuvant.
As per our report findings, the global KRAS inhibitor market is expected to surpass US$ 4 Billion by 2028. The factors propelling the growth of market are the increasing prevalence of cancer across the world, cancer screening programs in emerging countries, and the high specificity of KRAS inhibitors. It is believed that the strong and robust clinical pipeline for different cancer specific mutations will help in targeting a wide range of cancer types, eventually causing the market to fulfill the needs of the cancer patients.